Catalyst Dossier · compiled by CeliA 🧫
AbbVie Inc. (ABBV)
Pharmaceutical Preparations · market cap $382.5B · as of 2026-07-08
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-15 (est.)
Phase 2
Pipeline
20
programs
Upcoming events
8
next 90d+
Dossier
Ready
cached
AbbVie Inc. (ABBV) is a large-cap pharmaceutical company with a $450B market cap, approximately 57,000 employees, and 2025 revenues of $61.2B. The company carries a heavy debt load ($55.1B net debt) offset by a diversified late-stage pipeline spanning immunology, oncology, ophthalmology, and neurology, with multiple high-importance catalysts clustered in H2 2026.
The catalyst path
- 2026-11-15 (est.)Phase 2 · ABBV-932imp 7/10
- 2026-12-18 (est.)Phase 2 · MEDI0618imp 7/10
- 2027-01-15 (est.)Phase 3 · Upadacitinibimp 9/10
- 2027-02-15 (est.)Phase 2 · Ravagalimabimp 7/10
- 2027-03-15 (est.)Phase 3 · Cariprazineimp 9/10
- 2027-05-15 (est.)Phase 3 · Ubrogepantimp 9/10
- 2027-05-15 (est.)Phase 2 · Lutikizumabimp 7/10
- 2027-06-15 (est.)Phase 3 · Upadacitinibimp 9/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| AGN-242428 | Phase 2 | Dry Eye Disease |
| ABBV-8E12 | Phase 2 | Alzheimer's Disease |
| Bimatoprost (SR) | Phase 3 | Open-Angle Glaucoma |
| etanercept | Phase 3 | Moderate to Severe Plaque Psoriasis |
| ABT-450 | Phase 2 | Hepatitis C Virus |
| Etentamig | Phase 3 | Multiple Myeloma |
| ABBV-382 | Phase 2 | Crohn's Disease |
| Acalabrutinib | Phase 3 | Chronic Lymphocytic Leukemia |
| ABT-981 | Phase 2 | Erosive Hand Osteoarthritis |
| Elagolix | Phase 3 | Polycystic Ovary Syndrome |
| ABT-SLV187 | Phase 3 | Advanced Parkinson's Disease |
| Ranibizumab | Phase 2 | Neovascular Age-Related Macular Degeneration (nAMD) |
| ABT-450/r/ABT-267, ABT-333 | Phase 3 | Chronic Hepatitis C Infection |
| Paricalcitol | Phase 3 | Chronic Kidney Disease Stage 3 and 4 |
| ABT-493/ABT-530 | Phase 3 | Hepatitis C Virus Infection |
| sofosbuvir (SOF) | Phase 3 | Chronic Hepatitis C Virus |
| ABBV-142 | Phase 2 | Idiopathic Pulmonary Fibrosis |
| Standard of Care | Phase 3 | Non-Squamous Non-Small Cell Lung Cancer |
| Risankizumab SC | Phase 3 | Crohn's Disease |
| hydrocodone/acetaminophen extended release | Phase 2 | Chronic Low Back Pain |
Price & technical context
3-month
+15.0%
6-month
+29.0%
12-month
+18.9%
52-wk range
$197.38–$265.97
vs 50-day MA
+3.4%
vs 200-day MA
+15.1%
Realized vol
27.5%
Max drawdown
-21.5%
Daily closes through 2026-09-21. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for ABBV (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.